(Q37823576)

23 August 2017

1 reference

title

Current therapies for chronic hepatitis C. (English)

1 reference

23 August 2017

1 reference

McKenzie C Ferguson

1

1 reference

PubMed ID

21182362

23 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

23 August 2017

1 reference

23 August 2017

31

1 reference

23 August 2017

1

1 reference

23 August 2017

92-111

1 reference

Chronic hepatitis C virus infection: a review for pharmacists

23 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Trends in health care resource use for hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Acute hepatitis C virus infection: A chronic problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Boceprevir, an NS3 protease inhibitor of HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Treatment of hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Management of chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Treatment of chronic hepatitis C in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Interferon for Hepatitis C Virus in Hemodialysis--an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Approaching treatment for hepatitis C virus infection in substance users

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Management strategies for hepatitis C virus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.1.92

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.1.92

1 reference

23 August 2017

1 reference

PubMed ID

21182362